Abstract
Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 493-505 |
| Number of pages | 13 |
| Journal | Dermatology and Therapy |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2017 |
Fingerprint
Keywords
- Atopic dermatitis
- Cost-effectiveness
- Dupilumab
- Eczema
- Health economics
- Quality-adjusted life-years
ASJC Scopus subject areas
- Dermatology
Cite this
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. / Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent; Gadkari, Abhijit; Simpson, Eric; Graham, Christopher N.; Miles, La Stella; Mastey, Vera; Mahajan, Puneet; Sullivan, Sean D.
In: Dermatology and Therapy, Vol. 7, No. 4, 01.12.2017, p. 493-505.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
AU - Kuznik, Andreas
AU - Bégo-Le-Bagousse, Gaëlle
AU - Eckert, Laurent
AU - Gadkari, Abhijit
AU - Simpson, Eric
AU - Graham, Christopher N.
AU - Miles, La Stella
AU - Mastey, Vera
AU - Mahajan, Puneet
AU - Sullivan, Sean D.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.
AB - Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods: A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US100,000 and 150,000 per quality-adjusted life-year (QALY) gained. Results: In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be 28,770 at a 100,000 per QALY gained threshold, and 39,940 at a 150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion: Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of 29,000–40,000 at the 100,000–150,000 per QALY thresholds. Funding: Sanofi and Regeneron Pharmaceuticals, Inc.
KW - Atopic dermatitis
KW - Cost-effectiveness
KW - Dupilumab
KW - Eczema
KW - Health economics
KW - Quality-adjusted life-years
UR - http://www.scopus.com/inward/record.url?scp=85035209828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035209828&partnerID=8YFLogxK
U2 - 10.1007/s13555-017-0201-6
DO - 10.1007/s13555-017-0201-6
M3 - Article
AN - SCOPUS:85035209828
VL - 7
SP - 493
EP - 505
JO - Dermatology and Therapy
JF - Dermatology and Therapy
SN - 2190-9172
IS - 4
ER -